RxDoctor Payments Data

David Grossman, MD

Ophthalmology · Toms River, NJNPI 1407822380

Payments from drug & device makers

$917in general payments, 2019–2025

Across 13 payments — averaging $70.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harrow Eye, LLC$295
  • Biotissue Holdings Inc.$269
  • Sight Sciences, Inc.$132
  • AbbVie$105
  • Alcon$88
  • Oyster Point Pharma, Inc.$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$917100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$917 in reported general payments places this provider in the 35th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$638,471
Medicare patients
1,955
Services billed
5,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine264$385,418
Cyclosporine172$123,534
XiidraLifitegrast69$96,365
LumiganBimatoprost78$39,034
Travoprost111$27,194
Prednisolone Acetate777$23,648
Brimonidine Tartrate85$12,057
Latanoprost724$11,287
Tobramycin-DexamethasoneTobramycin/Dexamethasone272$10,559
Ketorolac Tromethamine550$8,629
Alphagan PBrimonidine Tartrate11$4,199
Timolol Maleate90$3,393
SimbrinzaBrinzolamide/Brimonidine Tart14$3,385
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$3,163
Brinzolamide17$3,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$105$428,651353 claims
AlconSimbrinza$88$3,38514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →